UroGen Achieves 72.2% Two-Year Event-Free Rate with ZUSDURI
UroGen’s Phase 3 ENVISION trial of ZUSDURI demonstrated a 79.6% complete response rate at three months and a 72.2% probability of remaining event-free at 24 months (95% CI: 64%, 79%). The median duration of response was not reached, marking the first FDA-approved non-surgical therapy for recurrent LG-IR-NMIBC.
1. ENVISION Trial Efficacy
The Phase 3 ENVISION trial enrolled adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a 79.6% complete response rate at three months. Kaplan-Meier analysis showed a 72.2% probability of remaining event-free at 24 months (95% CI: 64%, 79%), with median follow-up of 23.7 months and median duration of response not reached.
2. Clinical Advantages Over Surgery
ZUSDURI delivers mitomycin directly into the bladder via UroGen’s RTGel technology, allowing a six-week outpatient induction without maintenance. This non-surgical approach targets the estimated 59,000 annual LG-IR-NMIBC recurrences in the US, potentially reducing repeated TURBT procedures and associated risks in an elderly population with multiple comorbidities.
3. Commercial and Market Impact
As the first and only FDA-approved intravesical non-surgical therapy for recurrent LG-IR-NMIBC, ZUSDURI has potential to capture share of a high-recurrence niche. Publication of long-term durability data in a major urology journal may accelerate clinician adoption, support reimbursement discussions, and drive UroGen’s revenue growth trajectory.